Haleon Pakistan to invest nearly $5mn in Panadol Liquid packaging expansion
- Company says investment aimed at enhancing capacity
Haleon Pakistan Limited, formerly known as GlaxoSmithKline, has approved an investment of £3.58 million (USD 4.9 million) to expand and modernise its Panadol Liquid packaging line, as part of efforts to boost production capacity and improve operational efficiency amid rising demand.
The pharmaceutical disclosed the development in a notice to the Pakistan Stock Exchange (PSX) on Tuesday.
“Haleon Pakistan Limited is pleased to announce its decision to invest £3.58 million in the expansion and modernisation of its Panadol Liquid packaging line,” read the notice.
The listed company said that the ‘strategic investment’ is aimed at enhancing production capacity, improving operational efficiency, and meeting growing market demand for Panadol Liquid products.
According to the company’s website, these are the current liquid offerings available for children. Children’s Panadol Drops are formulated for ages 2 months to 2 years, while Children’s Panadol Liquid is suitable for children between 2 and 12 years. Meanwhile, Panadol Forte Suspension caters to older children between 6 to 12 years.
“The investment and associated financing have been approved by the Board of Directors of Haleon Pakistan Limited, and will include the procurement of advanced packaging machinery, upgrades to existing infrastructure, and implementation of quality control enhancements.
“This initiative reflects Haleon Pakistan’s commitment to innovation and its long-term growth strategy in the consumer healthcare segment,” read the notice.
Haleon Pakistan Limited was incorporated in Pakistan as a public limited company in 2015. The principal activity of the company is the manufacturing, marketing, and sale of consumer healthcare and over-the-counter health products.
The company is a subsidiary of “Haleon Netherlands B.V.’ while Haleon plc is the ultimate parent company.
Back in 2023, Haleon announced to invest around $10 million in its manufacturing facility at Jamshoro, Sindh, for Panadol base portfolio production, including Panadol 500mg and Panadol Extra tablets.
Comments